CDK4 and acute kidney injury: Paradoxically, preclinical studies indicate that targeted inhibition of the CDK4/6 pathway with ribociclib may exert nephroprotective effects by mitigating aberrant cell-cycle activation during cisplatin-induced AKI [31,32].